Abbvie Inc.

Abbott Laboratories Corporation

Robert K Hickman

Sushil G Devare

John R Hackett

Catherine A Brennan

Alan M Golden

Julie Yamaguchi

Scott T Ennis

Barbara Perilli-Palmer

Min Wan

Qing Huang

Cheryl L Weed

Ivan Correia

Anadruzela S Vallari

Vincent A Varitek, Jr

Elizabeth C Necklaws

Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.

Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography

Isolation and purification of anti-IL-13 antibodies using protein A affinity chromatography

Attachable tool and dust tray for artist's easel

Attachable artist's easel

Attachable tool tray for artist's easel

Described herein are methods for isolating and purifying antibodies from a sample matrix. One aspect of the present disclosure is directed to viral reduction/inactivation of samples generated in the various steps of antibody purification. In a particular aspect, methods herein employ an acidification step followed by one or more chromatography steps. The chromatography steps can include one or more of the following chromatographic procedures: ion exchange chromatography, affinity chromatography, and hydrophobic interaction chromatography.

Viral inactivation during purification of antibodies cross reference to related applications

Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.

Isolation and purification of antibodies using protein a affinity chromatography

Isolation and purification of antibodies using protein A affinity chromatography

Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.

Antigen constructs useful in the detection and differentiation of antibodies to HIV

Growing community of inventors

Worcester, MA, United States of America

Robert K Hickman